Clinical and Laboratory Features of Myelofibrosis and Limitations of Current Therapies

Abstract: Myelofibrosis (MF) is a life-threatening clonal stem cell malignancy characterized by progressive bone marrow fibrosis and ineffective hematopoiesis. The term “MF” encompasses primary myelofibrosis (PMF) as well as 2 other phenotypically similar malignancies: post-polycythemia vera (PV) MF (PPV-MF) and post-essential thrombocythemia (ET) MF (PET-MF). The World Health Organization classification system for myeloid malignancies recognizes PMF, PV, ET, and chronic myeloid leukemia (CML) as the “classic” myeloproliferative neoplasms (MPNs). Patients with low- or intermediate-1-risk disease have a median survival of 6–15 years, in contrast to those with intermediate-2- or high-risk disease, which is associated with a considerably worse prognosis. Following transformation into (secondary) acute myeloid leukemia (AML), the prognosis of MF is even worse, with a median survival of 3 months or less. Due to the heterogeneous nature of MF, the diagnosis and treatment of this malignancy can be challenging. At present, the only treatment that can be applied with curative intent is allogeneic stem cell transplantation (SCT), whereas no other specific therapies exist that are approved by the US Food and Drug Administration (FDA) for MF. Since most patients with MF appear not to be eligible for allogeneic SCT, patients are often treated by conventional “older” drugs such as androgens and hydroxyurea (HU; hydroxycarbamide), with the principal objective being palliation. Following the establishment of a causal role of a specific mutation in the Janus kinase type 2 (JAK2) gene, namely JAK2V617F, in the molecular pathogenesis of MPNs in 2005, many efforts have been directed towards the development of novel JAK1/JAK2 inhibitors. Other investigative approaches include immunomodulatory agents, histone deacetylase inhibitors, hedgehog inhibitors, and others. Recently, the positive results of the first in class of the JAK1/JAK2 inhibitors, ruxolitinib (formerly INCB18242), from 2 large phase III studies were presented and are discussed herein.
Target Audience
This activity has been designed to meet the educational needs of oncologists, hematologists, and other health care professionals involved in the management of patients with myelofibrosis.

Statement of Need/Program Overview
Myelofibrosis is a rare, clonal, hematologic neoplastic condition with a median survival ranging from 27 months to 5.7 years. It is characterized by splenomegaly, bone marrow fibrosis, anemia, and debilitating constitutional symptoms, which are thought to be related to high levels of circulating inflammatory cytokines. Splenomegaly can have a severe effect on quality of life, due to symptoms such as decreased activity, early satiety, abdominal pain or discomfort, and cough. The prognosis of myelofibrosis patients varies greatly according to disease characteristics. Stem cell transplantation may be curative in a small subset of patients, but this approach is associated with significant risk. Pharmacotherapy is directed toward palliation of symptoms. With the recent discovery that most myeloma patients have JAK2, MPL, and TET2 mutations, research is focusing on novel agents that target these pathways. Clinical trials have demonstrated benefit with such agents in terms of shrinkage of splenomegaly and improvement in constitutional symptoms.

Educational Objectives
After completing this activity, the participant should be better able to:

- Describe the importance of new study findings in the form of selected abstracts/poster summaries in the natural history of myelofibrosis
- Explain the therapeutic limitations of current therapies in the management of myelofibrosis
- Integrate into clinical practice the latest knowledge and methods for diagnosing and treating patients with myelofibrosis in an effort to improve current prognosis statistics
- Identify future research directions for all therapies in myelofibrosis

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Millennium Medical Publishing. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this journal-based CME activity for a maximum of 1.25/AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest or a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

Stephanie A. Gregory, MD—No real or apparent conflicts of interest to report.
Ruben A. Mesa, MD—No real or apparent conflicts of interest to report.
Ronald Hoffman, MD—No real or apparent conflicts of interest to report.
Jamile M. Shammo, MD—Contracted research: Incyte Corporation.

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. Jacquelyn Matos: No real or apparent conflicts of interest to report.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the period September 2011 through September 30, 2012, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CE by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 8153. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Media
Monograph

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Millennium Medical Publishing, and Incyte Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Millennium Medical Publishing, and Incyte Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©2011 Millennium Medical Publishing, Inc., 611 Broadway, Suite 310, New York, NY 10012. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form.
In 1951, Dr. William Dameshek first described a group of disorders—including polycythemia vera (PV), essential thrombocytopenia (ET), and myelofibrosis (MF)—that had overlapping clinical and laboratory findings. Dameshek argued that, given the difficulties in distinguishing among PV, PMF, and ET, it might be easiest to consider them “closely interrelated.” As these disorders were all characterized by bone marrow proliferation, Dameshek coined the term myeloproliferative disorders (MPDs).

I was a Fellow in Hematology from 1970–1972, during which time, therapy for myelofibrosis (MF) was purely palliative, and we depended on transfusions for the treatment of symptomatic anemia, along with folic acid and iron (if iron-deficiency anemia was present). Hydroxyurea (HU; also known as hydroxycarbamide) was prescribed if a patient developed leukocytosis or symptomatic splenomegaly. When a patient’s spleen continued to increase in size, and the white count and platelet counts dropped to dangerously low levels, we promptly called in our “best surgeon” to remove the patient’s spleen, stating that we had a 50% chance that the cytopenias would improve. The counts did improve in most patients, but often the liver would become massively enlarged, and most patients eventually developed ascites with signs of extramedullary hematopoiesis (EMH). Within 2 years, most of our patients had died.

The progress that has taken place in our understanding of the biology of these disorders in the past 50 years is astonishing. To discover a mutation that accounts for the cardinal pathophysiologic features of these neoplasms and lend impetus to the development of JAK2 inhibitors. Several such novel agents are currently in clinical trials. It is noteworthy that, excluding anagrelide, there are currently no agents approved by the US Food and Drug Administration (FDA) for the treatment of MPNs, and there is, therefore, a great need for new—and importantly, efficacious—therapies for patients with MPNs.

This “roundtable” monograph reviews the current and emerging management of patients with MF. The discussants are established experts in this field, and I hope you enjoy the discussion.

Acknowledgment

Dr. Gregory has no real or apparent conflicts of interest to report.

References

MF is a life-threatening clonal stem cell malignancy characterized by progressive bone marrow fibrosis and ineffective hematopoiesis. MF is a highly heterogeneous disorder with regard to age of onset, phenotypic manifestations, presenting features, and prognosis. Thus, optimal management of this disorder can be quite challenging and requires an understanding of the individual patient’s prognosis and ability to tolerate different therapies. Current diagnosis of MF is based on recently updated World Health Organization (WHO) criteria and includes morphologic, cytogenetic, clinical, and molecular assessments.1

Among the MPNs, MF induces the most morbidity and is associated with the poorest life expectancy.2 The estimated incidence of MF in the United States is 0.4–0.7/100,000 person/years.3 The disease predominantly affects elderly patients, with a median age of 65 years at onset, although up to 20% of patients are younger than 55 years when diagnosed.3 The median survival in primary myelofibrosis (PMF) is estimated at 6 years, and the causes of MF-related death include leukemic transformation, bone marrow failure, and complications from thrombosis and bleeding. After the disease transforms into secondary AML, the median survival is often less than 3 months.3,4 Several adverse prognostic factors for survival have been identified at diagnosis, including advanced age, anemia, leukocytosis, and an abnormal karyotype.5

Although the pathogenetic origins of MF can vary from patient to patient, the disease occurs both in individuals with apparently de novo MF and in those who developed MF from a clear antecedent MPN—either PV or ET (post-ET/PV MF). The precise disease-originating molecular event(s) leading to an abnormal clone in MF remain(s) currently unknown. Nonetheless, MF is associated with genetic mutations that induce abnormal cytokine expression, clonal myeloproliferation, and dysregulation of kinase signaling, and these mutations “drive” the clinicopathologic and laboratory features of this disease.6 The discovery of the JAK2V617F mutation in a significant majority of patients with MPNs led to the development of a number of novel JAK2 inhibitor compounds, which are now in clinical trials.

As of August 2011, there are no FDA-approved agents specifically for patients with MF, and, importantly, no agents have clearly demonstrated an ability to change the natural history of the disease. Historically, management of MF has included allogeneic SCT for a highly selected subgroup of severely afflicted patients, or palliative interventions in efforts to relieve constitutional symptoms related to splenomegaly (eg, hydroxyurea, splenic radiation, or splenectomy) or anemia (eg, androgens or erythropoietin).2 Currently available non-SCT therapies have led to neither significant nor sustained benefit with regard to control of splenomegaly and symptoms in MF patients; further, none of these therapies have been shown to result in prolonged survival. Allogeneic stem cell transplantation (SCT) remains the only therapy with curative intent in MF, but it is associated with substantial morbidity and mortality.3

References

The Natural History of Myelofibrosis

Ruben A. Mesa, MD

The development of reticulin and/or collagen fibrosis in the bone marrow space in myelofibrosis (MF) contributes to insufficient hematopoiesis followed by worsening cytopenias, resulting in significant morbidity and mortality. Historically, the term MF is sometimes—erroneously—used interchangeably with a variety of conditions, such as other malignancies and infections that can also result in bone marrow fibrosis. Myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) is a non-clonal bone marrow reaction to clonal proliferation, and it occurs primarily in 1 of 3 settings, according to the nomenclature established by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Patients with primary myelofibrosis (PMF) are generally diagnosed in the fibrotic stage, as defined by several major and minor WHO criteria. Although PMF seemingly arises de novo, from a histopathologic standpoint, the bone marrow fibrosis component of the disease represents a polyclonal response to an existing myeloproliferative process; indeed, PMF patients can undergo an initial phase of granulocyte and megakaryocyte proliferation prior to the advent of bone marrow fibrosis. MF can also follow clinically overt PV or ET; these settings are termed “post-PV MF” and “post-ET MF,” respectively; nevertheless, the basis for the development of bone marrow fibrosis in these 2 latter forms of MF seems to be identical to that of PMF (see above). All 3 types of MF (ie, PMF, post-PV MF, and post-ET MF) share common features of an advanced MPN, including cytogenetic abnormalities and an increased risk of transformation to a blastic phase. Since these conditions are clinically very similar and have not shown differences in response rates in therapeutic trials, the term “MPN-MF” has been recently proposed to encompass all 3 disorders.

Pathogenesis and Natural History

The precise molecular mechanisms underlying clonal myeloproliferation in MPN and the subsequent development of MF remain enigmatic. The principal pathogenic event “driving” the clinical, pathologic, imaging, and laboratory features of MF appears to be a JAK2 mutation, but other events might also be important. The JAK family members, which consist of JAK1, JAK2, JAK3, and TYK2, are intimately associated with cytokine and other hematopoietic growth factor receptors. For JAK-dependent signaling to occur, ligand binding to a cognate transmembrane receptor attracts cytoplasmic JAKs to a specific intracellular protein-interacting domain of the receptor (which itself lacks a kinase domain). Immediately after that molecular aggregation occurs, JAKs are activated by autophosphorylation of tyrosine residues, triggering a cascade of signaling events, including the phosphorylation of signal transducers and activators of transcription (STATs). The most common mutation in the JAK2 allele in MPN patients, JAK2V617F, occurs within the autoinhibitory JH2 domain of the JAK2 enzyme. The valine (V) to phenylalanine (F) switch prevents the autoinhibitory actions of that domain, leading to constitutive (activating) phosphorylation and aberrant downstream signaling. In addition to the dominant JAK2V617F mutation, other JAK2-activating mutations—such as JAK2T877N in the kinase domain, JAK2D856K in the JH2 pseudokinase domain, and various JAK2 exon 12 mutations—have been found in a subset of MPN patients lacking JAK2V617F. Less common mutations have been found in MPL, LNK, CBL, TET2, ASXL1, IDH, IKZF1, and EZH2 genes. The individual frequency of the above-mentioned mutations, except for JAK2V617F, is too low for their consideration as therapeutic targets.

As noted above, clonal myeloproliferation in MF is accompanied by bone marrow fibrosis, from which the name of MF is derived historically. Although fibrosis is recognized as a secondary phenomenon, it remains pathognomonic for MF. In the prefibrotic stage, the bone marrow displays marked hypercellularity with several classes of atypical megakaryocytes and granulocytes, followed by reticulin collagen fibrosis or osteosclerosis in the fibrotic stage. The fibrotic stage is typically associated with leukoblastosis, hepatic splenomegaly, and extramedullary hematopoiesis (EMH), particularly in the spleen but also at other sites. Cellular abnormalities in MF are detected in a peripheral blood smear, which typically shows nucleated red blood cells and immature granulocytes.

The clinical phenotype of MF includes massive splenomegaly, profound constitutional symptoms, progressive anemia, and cachexia. The development of anemia due to inadequate production of cells in the bone marrow can occur in all 3 types of MF, and is most pronounced in PMF. Anemia is least common in post-PV MF patients, because they sometimes retain the prior erythropoietic “drive” that existed during the PV phase of the illness. Bone marrow fibrosis results in leukocytosis and abnormal release of immature cells, cytokines, and chemokines into the peripheral blood. Immature cells—including myelo-
cytes, metamyelocytes, lymphoblasts, and other early myeloid precursors—are predisposed to sequestration in the spleen, resulting in ineffective hematopoiesis. Aberrancy in cell-cell interactions involving megakaryocytes, monocytes, and neutrophils contributes to abnormal peripheralization of CD34+ endothelial cells and myeloid progenitors. Elevated plasma levels of proinflammatory cytokines may also be linked to disease-associated constitutional symptoms and cachexia. A recent study showed that increases in interleukin-8 (IL-8), IL-10, IL-15, or IL-2 receptor (IL2R) were associated with inferior overall survival in myelofibrosis (MF), suggesting that inflammatory cytokines might affect survival in MF.

MF can cause a tremendous burden of symptoms, as shown in a prospective study of 128 MF patients that was presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. Worsening fatigue, abdominal discomfort, insomnia, decreased mental concentration, early satiety, intimacy problems, sad mood, night sweats, dizziness, cough, and bone pain are present in over 50% of patients with MF. Weight loss and fever occur in 30–50% of patients.

The natural history of MF is heterogeneous, and patients vary widely in the presence of symptoms, transformation to AML, and cytopenias. Early or prefibrotic MF can often behave like ET and PV, with an increased risk of vascular events, such as bleeding and thrombosis. In some patients, the prefibrotic phase can persist for more than 10 years before MF occurs. Development of overt MF is accompanied by constitutional symptoms, organomegaly, extramedullary hematopoiesis (EMH), and cytopenia. Progression to AML occurs in 10% or more of patients, particularly in younger patients. The natural history of MF patients who progress to AML is exceedingly poor. One study showed that the median survival of patients with PMF who transformed to acute leukemia had a median survival of less than 6 months. Patients who received only supportive care had a median survival of only 3.3 months.

Discussion

**H&O** Acute myeloid leukemia (AML) is usually defined as more than 20% of myeloblasts circulating in the peripheral blood, but in the case of MF, the bone marrow is so fibrotic that the myeloblasts would not be able to fit into such an environment. How do you feel about diagnosing AML in that setting?

**Ruben A. Mesa, MD** We know that an increase in peripheral blood myeloblasts in MF is not the same as having increased myeloblast counts in myelodysplastic syndromes (MDS) or de novo AML. In these latter malignancies, there are so many myeloblasts in the bone marrow that they literally “spill over,” causing an increase in peripheral myeloblast circulation. Now, we recognize that the presence of myeloblasts in the blood is a negative prognostic factor. We recognize that MF patients can have 1–10% of myeloblasts without a clear change in natural history. In contrast, as we have observed in research from the Mayo Clinic and from M.D. Anderson, MF patients with greater than 10% of myeloblasts in their peripheral blood clearly develop a natural history that is much more aggressive and accelerated. These patients tend to have poorer survival and tend to progress towards AML. Although the relationship is not necessarily the one-to-one relationship we might experience in other illnesses, a sustained myeloblast count at or above 20% in the peripheral blood can result in a prognosis as poor as that of AML. Frequently, one can also demonstrate the 20% threshold in myeloblast count in the bone marrow as well.

**H&O** What are some issues with diagnosing MF, particularly in a community oncology setting?

**Ruben A. Mesa, MD** Earlier cases of MF that overlap with other myeloid disorders, such as myelodysplasia (MDS), can be difficult to diagnose. However, I do think that the diagnosis of MF has become easier in the current era, particularly if patients have the cardinal features of a big spleen and a fibrotic bone marrow. Major mimicking diseases that are important to distinguish are other malignancies, including chronic myelomonocytic leukemia (CMML) and hairy cell leukemia. In the latter disease, patients often present with fibrotic bone marrow and a large spleen, like in MF. It is clearly critical to distinguish between these malignancies, since the management is diverse. One must make sure that the disease is not CML with fibrosis, so excluding the presence of the BCR-ABL1 translocation is important. But that being said, diagnosis is relatively accurate for most overt MF cases.

**H&O** Clinically, is it better to address MF before it becomes secondary acute myeloid leukemia?

**Ruben A. Mesa, MD** Absolutely. At this point, our therapeutic interventions for patients who have progressed from MF to AML are relatively ineffectual. Currently, we do not necessarily have therapies that will prevent the onset of acute leukemia, but this is certainly a key goal of therapy. A patient being considered for an aggressive therapy such as allogeneic SCT should clearly be treated prior to the onset of acute leukemia.

**H&O** Were there any reports on the treatment of myelofibrosis at the ASCO meeting this year?

**Ruben A. Mesa, MD** Yes. There are multiple JAK2 inhibitors, including ruxolitinib, cyt387, and SB1518, that are currently being tested. Other novel investiga-
tional therapies being tested include pomalidomide, anti-TGF-α antibodies, and hedgehog inhibitors.

Certain combinations of these agents remain an area of interest. Combinations of novel therapies that come to mind could be, for example, a JAK2 (or JAK1/JAK2) inhibitor in combination with an immunomodulatory drug, such as pomalidomide or lenalidomide. Other potential combinations could include pegylated interferon-α, histone deacetylating agents, and mammalian target of rapamycin (mTOR) inhibitors.

Acknowledgment
Dr. Mesa has no real or apparent conflicts of interest to report.

References

Current Treatment Options

Ronald Hoffman, MD

Therapeutic decisions regarding MF are primarily determined by the patient’s disease severity. Individuals with early forms of MF are often asymptomatic and may require only observation (“watchful waiting”). Patients with advanced forms of the disease, characterized by worsening symptomatic splenomegaly, high peripheral blood myeloblast counts, and anemia, are seriously considered for treatment options with available agents. Currently, there is no firm consensus on the treatment of patients with MF. Physicians often select allogeneic SCT, pharmacologic drug therapies, red blood cell transfusions, or splenectomy, based on individual patient indications and eligibility.

Allogeneic SCT

Of the available MF therapies, at present allogeneic SCT remains the only curative treatment. Allogeneic SCT is preceded by the administration of either myeloablative or dose-reduced conditioning (non-myeloablative or reduced-intensity regimens) and followed by immunosuppressive therapy to prevent graft rejection and the development of graft-versus-host disease (GvHD). Since the risk of allogeneic SCT far outweighs the benefits in patients with earlier stages of the disease, patients with advanced MF are the most likely candidates for allogeneic SCT. Overall survival rates between 40% and 80% have been reported with allogeneic SCT,2 and the long-term survival of patients who are younger than 65 years of age with an HLA-matched sibling donor is between 50% and 60%. The survival rate of patients with unrelated donors is likely substantially lower due to the higher incidence of graft failure and GvHD. In a study of the use of targeted busulfan plus cyclophosphamide, the following factors were statistically significant for improved survival among allogeneic or syngeneic transplant patients with MF: high platelet count at transplantation ($P=0.01$ for PV/ET; $P=0.39$ for other diagnoses), younger patient age ($P=0.04$), and decreased comorbidity score ($P=0.03$).2 Given the high risk of surgery-related complications and delayed engraftment, splenectomy is not recommended prior to transplant. An analysis of splenectomized and non-splenectomized MF patients did not show a significant difference in the 3-year probability of survival between the 2 groups.3
Clinical Advances in Hematology & Oncology  Volume 9, Issue 9, Supplement 22  September 2011

Red Blood Cell Transfusions

MF patients frequently experience anemia and require red cell transfusions, which can result in iron overload. The use of either parenteral or oral iron-chelating agents can sometimes prevent this. Iron-chelating agents are usually administered after a patient has received 20 or more red blood cell transfusions, and these agents—in conjunction with transfusion therapy—can prevent organ damage and other iron overload syndromes. One study showed that iron-chelation therapy significantly improved the overall survival of red blood cell transfusion–dependent PMF patients.4

Pharmacologic Drug Therapies

The currently available drug therapies for MF are palliative rather than curative, as they have not been clearly proven to prolong survival or alter the natural history of the disorder. Further, even the palliative effect observed with the currently available agents is often unsatisfactory and short-lived. In clinical practice, the benefit of utilizing these drugs must be weighed against their known toxicities. Commercially available MF drugs typically attempt to target cytopenias, myeloproliferation, or both (Table 1).5

Therapy with interferon (IFN)-α has been utilized in MF patients based on its cytoreductive properties in vitro and in vivo. Histopathologically, IFN-α treatment has been shown to reverse cytopenias and bone marrow abnormalities in patients with earlier forms of MF, prior to the advent of extensive fibrosis.5 However, inconvenient dosing schedules and excessive toxicity have prevented the generalized use of recombinant human IFN-α. For example, in a phase II study of 11 treatment-naïve PMF patients, no clinically relevant improvement was observed in any patients, and 6 patients experienced unacceptable drug toxicity.6 There has been a recent resurgence of interest in the use of IFN-α following the development of pegylated IFN-α2a (PEG-IFN-α), which has a better toxicity and pharmacokinetic profile compared with conventional IFN-α. One study showed that the majority of patients experienced complete remission or major responses following treatment with PEG-IFN-α.7

Assessment of vitamin and iron deficiencies in anemic MF patients is also important, as such deficiencies can contribute to cytopenias. If appropriate supplementation does not resolve the anemia, erythropoiesis-stimulating agents (ESAs) or androgenic steroids can be used. In a small study by Cervantes and colleagues, 9 out of 20 (45%) PMF patients showed a favorable response rate after treatment with 30,000 units of recombinant human erythropoietin (rHuEPO).8 A serum erythropoietin (EPO) level of less than 125 U/L was associated with a significantly higher likelihood of response. In a meta-analysis of PMF patients with anemia, Rodriguez and coworkers reported a response rate of 33% with rHuEPO doses of up to 600 units per kg per week, and patients with endogenous EPO levels of less than 125 U/L again had the highest likelihood of response.9 Thus, erythropoietin treatment should focus on patients with anemia and inadequate EPO levels. Parenthetically, in the United States, the Centers for Medicare & Medicaid Services (CMS) do not reimburse the use of ESAs for MF patients, so access to erythropoietin or erythropoietin derivatives can be challenging for relatively large patient populations.

Danazol, a nonvulirizing androgenic steroid, is sometimes useful to treat anemia in MF patients. One study showed that 4 out of 7 (57%) PMF patients treated with danazol 600–800 mg/day achieved a complete or partial response, and 3 responders also showed a significant

---

### Table 1. Commercially Available Pharmacotherapy for Palliation of Myelofibrosis

<table>
<thead>
<tr>
<th>Agent</th>
<th>Myelofibrosis (Disease Component)</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythropoietin</td>
<td>Cytopenias</td>
<td>Growth factor</td>
</tr>
<tr>
<td>Danazol</td>
<td>Cytopenias</td>
<td>Androgen</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>Cytopenias Myeloproliferation</td>
<td>Immunologic modulator</td>
</tr>
<tr>
<td>Interferon-α</td>
<td>Myeloproliferation</td>
<td>Immunologic modulator</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Cytopenias Myeloproliferation</td>
<td>Immunologic modulator</td>
</tr>
<tr>
<td>Hydroxyurea (Hydroxycarbamide)</td>
<td>Myeloproliferation</td>
<td>Antineoplastic</td>
</tr>
<tr>
<td>Busulfan</td>
<td>Myeloproliferation</td>
<td>Alkylator</td>
</tr>
<tr>
<td>Melphalan</td>
<td>Myeloproliferation</td>
<td>Alkylator</td>
</tr>
</tbody>
</table>
increase in platelet counts. A 37% response rate was achieved in a study of 30 PMF patients who were given danazol 600 mg/day, with progressive tapering to the minimum effective dose in responders after 6 months.

The anti-inflammatory and antiangiogenic properties of immunomodulatory drugs (IMiDs) may aid in the treatment of MF, which is characterized by increased angiogenesis and the production of cytokines. Lenalidomide and thalidomide are 2 immunomodulatory agents used to treat MF-associated complications, including anemia, thrombocytopenia, and splenomegaly. A phase II trial of MF patients found that lenalidomide plus prednisone therapy resulted in significantly longer response duration (median: 34 months) than single-agent lenalidomide or thalidomide (median: 7 and 13 months, respectively; P=.042), and fewer patients (P=.001) discontinued lenalidomide plus prednisone therapy (13%) because of side effects than patients receiving single-agent therapies (32–39%). These results suggest that the combination of lenalidomide plus prednisone is safer and more effective than single-agent thalidomide or lenalidomide, although lenalidomide is a myelosuppressive agent and should be administered with caution. Neuropathy, constipation, cytopenias, and depression are among the side effects of these drugs. Pomalidomide, another immunomodulatory agent, was shown to improve anemia in MF patients in a phase II trial. Following low-dose (0.5 mg) administration of pomalidomide alone, 14 of 24 patients (58%) with platelet counts at or less than 100 x 10^9 cells/L experienced a greater than 50% increase in platelet counts. There were no spleen responses, and grade 3/4 thrombocytopenia occurred in 2% of patients. There were no reports of grade 3/4 neutropenia.

The development of splenomegaly and the resulting splenic infarcts in MF patients can lead to premature satiety and weight loss. The reduction in spleen size is therefore a paramount therapeutic target for the treatment of MF patients. The chemotherapeutic agent hydroxyurea (HU) can be administered with acceptable toxicity for the management of splenomegaly, although the doses are sometimes limited by the patient’s degree of cytopenia, and the effect has been described only in the context of consecutive patients treated in tertiary referral centers (rather than that of randomized clinical trials). In the event that HU is not effective for control of splenomegaly, the use of low doses of the alkylating agents busulfan or melphalan intermittently can result in satisfactory responses. In a study by Petti and associates, patients with PMF were treated with 2.5 mg of oral melphalan 3 times a week during a 7-year period. After a median of 7 months of therapy, 66% of patients achieved a response, although blastic transformation occurred in 26% of the cohort. The latter effect of enhanced secondary leukemogenesis has tempered any remaining enthusiasm for the long-term use of alkylators in MF.

In a small subset of patients with persistent symptomatic splenomegaly, strong consideration should be given to surgical splenectomy, either laparoscopically or through a full surgical approach. Patients should receive appropriate immunizations prior to splenectomy, and the surgery must be performed by an experienced abdominal surgeon who is intimately familiar with spleen removal in MF patients. Careful selection of patients eligible for splenectomy is important, as the surgery is associated with significant morbidity of 5–10% due to infection, thrombohemorrhagic complications, or both.

**Discussion**

**H&O** Which patients are optimal candidates for transplantation in MF?

**Ronald Hoffman, MD** I often consider patients who have advanced disease for an allogeneic SCT, provided, of course, that the patient supports this option and is suitable for the procedure, particularly with regard to potential comorbid conditions and identification of an appropriate HLA-identical donor.

**H&O** What is the age range for transplanting patients with advanced myelofibrosis?

**Ronald Hoffman, MD** We transplant patients up to age 70 years. For those patients who do not have a sibling donor but do have an unrelated HLA matched donor, we transplant up to age 65 years.

**H&O** Are there patients who are clearly not candidates for a splenectomy?

**Ronald Hoffman, MD** An evaluation by an anesthesiologist and a surgeon is required to determine whether a patient is a reasonable surgical candidate. Patients with disseminated intravascular coagulopathy (DIC) or ongoing thrombosis are at an extremely high risk of developing complications. But if the patient has a performance status that would allow for general anesthesia and abdominal surgery, one could proceed with spleen removal.

**Acknowledgment**

Dr. Hoffman has no real or apparent conflicts of interest to report.

**References**


New Approaches to Diagnosing and Treating Myelofibrosis

Jamile M. Shammo, MD

The diagnosis and classification of MPNs have continued to evolve since its first nosologic descriptions in 1951. MF can develop as either de novo (PMF) or in the setting of antecedent polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). Current diagnosis of PMF is based on the 2008 WHO classification, which was recently updated following the discovery of the JAK2V617F mutation in the majority of PV patients and in about 50–60% of patients with ET and MF. The WHO guidelines for the diagnosis of MF require that 3 major criteria and 2 out of 4 minor criteria be met to diagnose a patient with this entity.1–2 The diagnosis of post-PV or post-ET MF is made according to IWG-MRT criteria, which requires the documentation of prior PV and ET along with the presence of bone marrow fibrosis, a grade of 2–3 on a standard scale, and 2 minor criteria (Table 1).1,3

In all 3 MF variants, typical diagnostic indicators include anemia, peripheral blood leukoerythroblastosisis, bone marrow fibrosis, osteosclerosis, and increased degree of angiogenesis. Notably, the distinction between ET-associated bone marrow fibrosis and a prefibrotic PMF is clinically relevant, since leukemiamfree survival and overall survival are significantly lower in the latter.1

Prognosis in MF

The prognosis of advanced MF patients remains poor.4 Determining an accurate prognosis for MF patients is crucial for treatment decisions, but it has been challenging due to the heterogeneous nature of MF. Retrospective trial analyses have led to the development of several prognostic scoring systems for MF. A study of 1,024 PMF patients by the IWG-MRT showed that age over 65 years, presence of constitutional symptoms, Hb levels less than 10 g/dL, leukocyte count greater than 25 x 109/L, and circulating myeloblast cells ≥1% were associated with decreased survival. These variables were assigned a score, the sum of which identified 4 groups: low risk (0 variables), intermediate risk-1 (1 variable), intermediate risk-2 (2 variables), or high risk (3 or more variables); with median survival of 11.3, 7.9, 4.0, and 2.3 years, respectively (P<.001).5 This study, which led to the creation of the International Prognosis Scoring System (IPSS) for MF, displayed higher predictive accuracy, replicability, and discriminatory power compared to previous models.

Although the IPSS model remains a landmark in the prognostication of MF, it can be used only to stratify patients at the time of diagnosis. Because the acquisition of additional risk factors during the disease course might
affect patient outcome, a dynamic prognostic model was subsequently developed to account for modifications of the risk profile after diagnosis. The Dynamic International Prognostic Scoring System (DIPSS) analyzed the 5 IPSS variables as time-dependent covariates in a multivariate Cox proportional hazard model, allowing for the prognostic assessment of PMF patients at any time during their clinical course.6 The more recently published “DIPSS Plus” model further refined the MF scoring system by combining prognostic information from DIPSS with karyotype, platelet count, and transfusion status to predict overall survival in MF. Unfavorable karyotypes included +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), or 11p23 rearrangement. Thrombocytopenia (platelets <100 x 10^9/L) and red cell transfusion dependence were additional prognostic factors for MF survival.7 The DIPSS Plus model has the potential to identify seemingly low-risk patients using both the original IPSS factors along with the added factors that are independent of IPSS; this newer system needs to be independently validated, and further research is necessary before its wider acceptance. Notably, the IPPS, DIPPS, and DIPPS Plus scoring systems do not include assessment of molecular markers, although future prognostic scoring systems might incorporate known molecular markers, such as JAK2V617F.

### Table 1. Diagnostic Criteria for PMF, Post-PV, and Post-ET Myelofibrosis4-3

<table>
<thead>
<tr>
<th>WHO diagnostic criteria for PMF requires meeting all 3 major criteria and 2 minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
</tr>
<tr>
<td>- Megakaryocyte proliferation and atypia, usually accompanied by either reticulin or collagen fibrosis. In the absence of significant reticulin fibrosis, megakaryocyte changes must be accompanied by increased bone marrow cellularity</td>
</tr>
<tr>
<td>- Not meeting WHO criteria for CML, PV, MDS, or other myeloid neoplasms</td>
</tr>
<tr>
<td>- Demonstration of JAK2V617F or another clonal marker, or no evidence of reactive marrow fibrosis</td>
</tr>
<tr>
<td><strong>Minor criteria</strong></td>
</tr>
<tr>
<td>- Leukoerythroblasticosis</td>
</tr>
<tr>
<td>- Increased serum LDH</td>
</tr>
<tr>
<td>- Anemia</td>
</tr>
<tr>
<td>- Palpable splenomegaly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IWG-MRT criteria for post-PV/ET requires meeting both major criteria and 2 minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
</tr>
<tr>
<td>- Previous PV or ET diagnosis as defined by the WHO criteria</td>
</tr>
<tr>
<td>- Bone marrow fibrosis grade 2–3 (on 0–3 scale, European classification) or 3–4 (on 0–4 scale, standard classification)</td>
</tr>
<tr>
<td><strong>Minor criteria</strong></td>
</tr>
<tr>
<td>- Leukoerythroblastic peripheral blood picture (for both PV and ET)</td>
</tr>
<tr>
<td>- Increasing splenomegaly (for both PV and ET)</td>
</tr>
<tr>
<td>- Development of at least 1 of 3 constitutional symptoms: &gt;10% body weight loss in 6 months, night sweats, unexplained fever (for both PV and ET)</td>
</tr>
<tr>
<td>- Anemia or sustained loss of requirement for phlebotomy in the absence of cytoreductive therapy (for PV)</td>
</tr>
<tr>
<td>- Anemia and decreased Hb level ≥2 g/dL from baseline (for ET)</td>
</tr>
<tr>
<td>- Increased serum LDH (for ET)</td>
</tr>
</tbody>
</table>

CML=chronic myelogenous leukemia; ET=essential thrombocythemia; Hb=hemoglobin; IWG-MRT= International Working Group for Myelofibrosis Research and Treatment; LDH=lactate dehydrogenase; MDS=myelodysplastic syndromes; PMF=primary myelofibrosis; PV=polycythemia vera; WHO=World Health Organization.

### New MF Therapeutic Strategies

The landmark discovery of the JAK2V617F mutant allele in a high percentage of PV, ET, and PMF patients ignited interest in the use of JAK2 inhibitors for the treatment of MF (Table 2).8 Overall, some JAK2 inhibitors have shown significant effects in the reduction of splenomegaly, which is often evident within the first 1–2 months of treatment. All JAK2 inhibitors currently in clinical trials inhibit the JAK-signal transducer and activator of transcription (STAT) pathway, but they appear not to be specific for the JAK2V617F mutant protein only. Efficacy has been noted in patients regardless of JAK2 mutation status.9

The agent in this class that is furthest in development is ruxolitinib (formerly INCB18424), an equipotent JAK1 and JAK2 inhibitor, which has undergone phase III trials in the United States, Canada, and Australia, as well as Europe. In a phase I/II trial of 153 patients with JAK2V617F-positive or JAK2V617F-negative PMF, post-ET MF, or post-PV MF, ruxolitinib was associated with marked and durable clinical benefits.10 At a 15-mg twice-daily starting dose followed by individualized dose titration, 17 of 33 patients (52%) had a rapid objective response (>50% reduction of splenomegaly, as assessed by palpation). Patients with debilitating symptoms, includ-
ing fatigue, night sweats, weight loss, and pruritus, also showed improvement. Ruxolitinib therapy was associated with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients. This agent was similarly effective in patients both with and without the JAK2\textsuperscript{V617F} mutation, suggesting that some of the effects of this drug might be due to other alterations in the JAK-STAT pathway.\textsuperscript{8} Serial administration of the MF Symptom Assessment Form (MF-SAF) as a tool for symptom assessment during this trial also showed significant improvement in MF-associated symptoms, and responses were equivalent regardless of MF subtype or JAK2\textsuperscript{V617F} mutation status.\textsuperscript{11}

Currently, one global phase III clinical trial program of ruxolitinib in MF (the COMFORT [Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment] I and II trials) has been completed, while another large, global, phase III clinical study (RESPONSE [Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care Trial in Patients With PV]) is under way. COMFORT-I study was a double-blind, placebo-controlled trial with a 1:1 randomization. The study met its primary efficacy endpoint, showing that 41.9% of ruxolitinib-treated patients experienced a 35% or greater reduction in spleen volume at 24 weeks as measured by magnetic resonance imaging (MRI) or computed tomography (CT), compared with 0.7% of patients in the placebo arm (\(P<.0001\)). The vast majority of ruxolitinib-treated patients had some reduction in spleen volume, with a median reduction of 33%. In addition, the COMFORT-I study showed statistically significant, clinically meaningful improvements of symptoms, a key secondary efficacy endpoint.\textsuperscript{12} The COMFORT-II study, which was a 2:1 randomization, demonstrated that ruxolitinib produced a volumetric spleen size reduction of 35% or greater in 28.5% of MF patients compared to 0% of patients in the best available therapy (BAT) arm at 48 weeks (\(P<.0001\)). This trial also met its key secondary endpoint, with 31.9% of ruxolitinib-treated patients demonstrating a 35% or greater volumetric spleen size reduction compared to 0% in the BAT arm at week 24 (\(P<.0001\)). Data based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) scores showed a marked improvement in overall quality of life measures, functioning, and symptoms relative to the BAT arm.\textsuperscript{13} Ruxolitinib was well-tolerated by MF patients, with minimal nonhematologic adverse events, as well as transitory and predictable thrombocytopenia and anemia; the thrombocytopenia was managed via dose reductions.\textsuperscript{12,13}

### Table 2. JAK2-Inhibiting Agents in Clinical Trials\textsuperscript{a}

<table>
<thead>
<tr>
<th>Drug</th>
<th>JAK Inhibitory Activity Selectivity</th>
<th>Stage of Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruxolitinib (INCB18424)</td>
<td>JAK1, JAK2</td>
<td>Phase III (for myelofibrosis): COMFORT-I (placebo controlled)/COMFORT-II (best available oral/parenteral therapy–controlled)</td>
</tr>
<tr>
<td>TG101348/SAR302503</td>
<td>JAK2</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>CYT387</td>
<td>JAK1, JAK2, JAK3</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>SB1518</td>
<td>JAK2</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>LY2784544</td>
<td>Uncertain (reported to be JAK2\textsuperscript{V617F} mutant–specific)</td>
<td>Phase I</td>
</tr>
<tr>
<td>Lestaurtinib (CEP701)</td>
<td>JAK2</td>
<td>Phase II</td>
</tr>
<tr>
<td>AZD1480</td>
<td>JAK2</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>JAK2</td>
<td>Phase II</td>
</tr>
<tr>
<td>ITF2357 (Givinostat)</td>
<td>JAK2 (indirectly via histone deacetylation inhibition; this compound is not a direct JAK inhibitor)</td>
<td>Phase II</td>
</tr>
<tr>
<td>AT9283</td>
<td>JAK2</td>
<td>Phase I/II</td>
</tr>
</tbody>
</table>

COMFORT=Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; JAK=Janus kinase; PV=polycthemia vera; RESPONSE=Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea; JAK Inhibitor INC424 Tablets Versus Best Available Care Trial in Patients With PV.
Several other JAK inhibitors are in earlier stages of investigation. A phase I trial investigated the safety and efficacy of the oral JAK2-selective inhibitor TG101348 (also known as SAR302503) in 59 patients with high-risk or intermediate-risk PMF, post-PV MF, or post-ET MF. By 6 and 12 cycles of treatment, 39% and 47% of patients, respectively, showed a spleen response according to IWG-MRT criteria. Over half the patients achieved rapid and durable improvement in early satiety, fatigue, night sweats, pruritus, and cough following TG101348 treatment. TG101348 treatment also led to a significant decrease in the JAK2^{V617F} allele burden at 6 months in mutant-positive patients (P<.04). TG101348 had a modest effect on cytokine levels, and adverse effects included nausea, diarrhea, and vomiting, as well as anemia and thrombocytopenia (which were predictable due to the agent’s mechanism of action).

SB1518, a selective JAK2 inhibitor, has shown similar activity for MF-associated splenomegaly and symptom burden in phase I/II trials. In a report presented at the 2010 American Society of Hematology (ASH) meeting, significant reductions in spleen size and a trend for reduction in MF-associated symptoms were noted. SB1518 also does not seem to cause myelosuppression, although it does cause gastrointestinal disturbances in some patients. CYT387 (a JAK1 and JAK2 inhibitor) is in phase II testing. In a murine model, treatment with CYT387 normalized white blood cell counts, hematocrit, and spleen size, and it restored physiologic levels of inflammatory cytokines. Early clinical (late phase I) data have shown that CYT387 can reduce splenomegaly, control constitutional symptoms, and potentially improve anemia in PMF patients. LY2784544, an agent targeting mutant JAK2^{V617F}, is also being developed following encouraging in vitro and in vivo data; recruitment for a phase I trial of LY2784544 is ongoing.

Lestaurtinib (CEP-701), a mixed JAK2/fetal liver tyrosine kinase-3 (FLT3) inhibitor, was found to reduce splenomegaly in an open-label, phase II trial involving 40 advanced-phase PV and ET patients. In another phase II study, JAK2^{V617F}-positive MF patients were treated with 80 mg oral lestaurtinib twice daily. Only 6 out of 22 (27%) patients responded by IWG-MRT criteria, and no improvement was seen in bone marrow fibrosis or JAK2^{V617F} allele burden. Mild but frequent gastrointestinal toxicity was reported. Thus, lestaurtinib so far has shown only modest effects in PMF and post-PV/ET MF. Following encouraging preclinical results in various MPN preclinical models, 1 additional JAK2 inhibitor—AZD1480—is currently in phase I clinical trials.

Several JAK2 inhibitors are undergoing preclinical testing in vitro and in vivo. LS104, a novel non-ATP mimetic JAK2 inhibitor, strongly inhibited the growth of cytokine-independent endogenous erythroid colonies from JAK2^{V617F}-positive MPN patients. LS104 did not have a significant effect on the growth of myeloid colonies from normal control subjects. TG101209, a potent JAK2 inhibitor, effectively treated JAK2^{V617F}-induced hematopoietic disease in mice and suppressed the proliferation of human erythroleukemia cells expressing the JAK2^{V617F} mutation. Preclinical data regarding 2 additional novel JAK2 inhibitors, NS-018 and BMS-911543, were presented at the 2010 ASH meeting.

Although the development of JAK inhibitors has yielded positive clinical results, complete remission following their use in MF is still very rare. Off-target and non-JAK2 inhibitors, such as inhibitors of histone deacetylase (HDAC), are currently under investigation for the treatment of MF. HDAC inhibitors represent a novel class of chemotherapeutic drugs that can alter the acetylation status of both histone and non-histone proteins, thereby affecting a range of cellular functions in neoplastic cells. In vitro data have shown that the HDAC inhibitor ITF2357 preferentially inhibits proliferation of cells with the JAK2^{V617F} mutation. In a phase Ia study involving patients with PMF and post-PV/ET MF (n=13), PV (n=12), and ET (n=1), ITF2357 treatment was well-tolerated overall. Of the 13 MF patients, 2 patients had major responses and 2 patients had moderate responses. Another HDAC inhibitor, panobinostat (also known as LBH589), has demonstrated an ability to improve anemia and splenomegaly, and is being tested in a phase II, multicenter trial.

Inhibitors of farnesyl transferases and DNA hypermethylation are also of interest as potential non–JAK2 pathway targeting drugs. Administration of 600 mg/day of tipifarnib (R115777), a non-peptidomimetic farnesyltransferase inhibitor (FTI), to 34 PMF patients achieved a clinically relevant decrease in organomegaly in 11 patients (33%), but resulted in little improvement in anemia. Patient responses did not correlate with reductions in bone marrow fibrosis, neoangiogenesis, osteosclerosis, or resolution of baseline karyotypic abnormalities. Azacitidine and decitabine, 2 DNA methyltransferase inhibitors that induce reactivation of methylated genes, are FDA-approved for the treatment of patients with myelodysplastic syndromes (MDS), and are currently under investigation for PMF treatment in phase II trials.

Given the established response in a subset of patients with MF to immunomodulatory agents such as thalidomide and lenalidomide, there is continued interest in developing novel agents belonging to this class of drugs, such as pomalidomide, which has been evaluated at various dose levels in MF. Pomalidomide appears to have fewer myelosuppressive properties, which appear to be dose-dependent. Patients treated on clinical trials with pomalidomide demonstrated an improvement in their anemia, but the drug had a limited ability to control splenomegaly.
Finally, the use of interferon in this patient population continues to be under investigation, with a recent report demonstrating clinical benefit or stability in 80% of early MF patients with only grade 1 or 2 marrow fibrosis.25

**Future Directions in MF Management**

Future directions for MF therapies are likely to focus on additional molecular targets in MF disease pathways.11 Continued investigation into newly identified molecular aberrations, such as ASXL1 and LNK mutations, might yield additional novel therapeutic targets. Although most JAK inhibitors have been helpful in alleviating MF symptoms and controlling progressive splenomegaly, additional studies regarding long-term side effects, utility in early (prefibrotic) disease stages, activity in PV and ET, amenability to combination with other agents, and optimal dosage/duration are necessary.

**Discussion**

**H&O**

Transplant is usually reserved for high-risk patients, but are there any situations in which you would consider transplant in intermediate-risk patients?

*Jamie M. Shammo, MD*

The problem with MF patients in the intermediate-1 disease category (per IWG-MRT) is that there is a great deal of heterogeneity within this prognostic stratum, so it would be useful to apply a time-dependent scoring system to sort this specific group of patients and identify those who have a rapidly progressive disease and may benefit from an allogeneic transplantation. The decision to offer a stem cell transplant option to patients with MF in this category should be made on an individual basis.

**H&O**

Do you think the development of a JAK2 inhibitor will influence the decision of the timing of transplant?

*Jamie M. Shammo, MD*

I am not sure that the development or even the commercial availability of JAK2 inhibitors will necessarily impact the decision to recommend or consider allogeneic transplantation for patients with high-risk MF, as this approach continues to represent the only curative treatment option for this subset. Their availability, however, might influence who we consider for transplantation; for example, if a JAK2 (or JAK1/JAK2) inhibitor were to be incorporated into the management of patients debilitated by their disease, it might improve their chances of undergoing a stem cell transplant by improving their constitutional symptoms and performance status.

**Acknowledgment**

*Dr. Shammo has performed contracted research for Incyte Corporation.*

**References**

Myelofibrosis

Myelofibrosis is a life-threatening clonal stem cell malignancy characterized by:
- Progressive bone marrow fibrosis
- Ineffective hematopoiesis

The term "myelofibrosis" encompasses primary myelofibrosis and 2 other phenotypically similar malignancies:
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis

Allogeneic SCT in Myelofibrosis

- The only curative treatment of myelofibrosis
- Preceded by the administration of either myeloablative or dose-reduced conditioning (non-myeloablative or reduced-intensity regimens) and followed by immunosuppressive therapy to prevent graft rejection and the development of graft-versus-host disease
- Most often used in patients with advanced MF

Pharmacologic Therapy in Myelofibrosis

- The currently available drug therapies for myelofibrosis are palliative rather than curative, as they have not been clearly proven to prolong survival or alter the natural history of the disorder
- The palliative effect observed with the currently available agents is often unsatisfactory and short-lived
- In clinical practice, the benefit of utilizing these drugs must be weighed against their known toxicities
- Commercially available myelofibrosis drugs typically attempt to target cytopenias, myeloproliferation, or both

Myelofibrosis: Current Therapeutic Agents

- Ifosfamide has been shown to have a subjective and long-term benefit of symptoms in MF. Thalidomide has been associated with hematologic responses, decreasing transfusion requirements, and improvements in Quality of Life, but is associated with a risk of peripheral neuropathy
- Pegylated IFN-α2b has a better toxicity and pharmacokinetic profile compared with unpegylated IFN
- Corynebacterium parvum and thalidomide can be combined to alleviate symptoms in MF patients
- Imatinib is sometimes useful to treat anemia in myelofibrosis patients
- Hydroxyurea can be administered for the management of anemia in myelofibrosis

New Treatment Strategies in Myelofibrosis: JAK2 Inhibitors

- The landmark discovery of the JAK2V617F mutant allele is a high percentage of polycythemia vera, essential thrombocythemia, and primary myelofibrosis patients ignited interest in the use of JAK2 inhibition for the treatment of myelofibrosis
- Some JAK2 inhibitors have shown significant effects in the reduction of spleen size, which is often evident within the first 1–2 months of treatment
- All JAK2 inhibitors currently in clinical trials inhibit the JAK signal transducer and activator of transcription pathway, but they appear not to be specific for the JAK2-V617F mutant protein only
- Efficacy has been noted in patients regardless of JAK2 mutation status

Ruxolitinib in Myelofibrosis

- In a randomized placebo-controlled study, 114 patients treated with 1.5 mg/kg of ruxolitinib had a 35% reduction in spleen volume at 12 weeks, compared with 12% of patients in the placebo group. More than 90% of ruxolitinib-treated patients showed a significant reduction in spleen volume, with a median reduction of 39% (p < 0.001). Treatment side effects were generally mild to moderate and included symptoms of fatigue, fever, nausea, and hypertension.